414 related articles for article (PubMed ID: 27323812)
1. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
2. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
[TBL] [Abstract][Full Text] [Related]
3. ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer.
Sato T; Saito M; Nakajima S; Saito K; Katagata M; Fukai S; Okayama H; Sakamoto W; Saze Z; Momma T; Mimura K; Kono K
Gastric Cancer; 2023 May; 26(3):379-392. PubMed ID: 36811690
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.
Yan HB; Wang XF; Zhang Q; Tang ZQ; Jiang YH; Fan HZ; Sun YH; Yang PY; Liu F
Carcinogenesis; 2014 Apr; 35(4):867-76. PubMed ID: 24293408
[TBL] [Abstract][Full Text] [Related]
5. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
7. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
8. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Yang L; Yang G; Ding Y; Huang Y; Liu S; Zhou L; Wei W; Wang J; Hu G
Oncol Rep; 2018 Jul; 40(1):479-487. PubMed ID: 29767248
[TBL] [Abstract][Full Text] [Related]
10. ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
12. miR-7641 depletion suppresses proliferation of gastric cancer cells by targeting ARID1A.
Yang Y; Yin ZX; Wang ZY; Tian SB; Wang HC; Zhang FX; Li LP; Zheng C; Kong S
Anticancer Drugs; 2020 Apr; 31(4):368-376. PubMed ID: 31913196
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency
Yang L; Yang G; Ding Y; Dai Y; Xu S; Guo Q; Xie A; Hu G
J Cancer; 2018; 9(5):890-900. PubMed ID: 29581767
[TBL] [Abstract][Full Text] [Related]
14. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
15. DNA damage regulates ARID1A stability via SCF ubiquitin ligase in gastric cancer cells.
Jiang ZH; Dong XW; Shen YC; Qian HL; Yan M; Yu ZH; He HB; Lu CD; Qiu F
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(17):3194-200. PubMed ID: 26400522
[TBL] [Abstract][Full Text] [Related]
16. Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt.
Ye Y; Ge YM; Xiao MM; Guo LM; Li Q; Hao JQ; Da J; Hu WL; Zhang XD; Xu J; Zhang LJ
J Gastroenterol; 2016 Mar; 51(3):230-40. PubMed ID: 26201869
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.
Du L; Chen X; Cao Y; Lu L; Zhang F; Bornstein S; Li Y; Owens P; Malkoski S; Said S; Jin F; Kulesz-Martin M; Gross N; Wang XJ; Lu SL
Oncogene; 2016 Sep; 35(35):4641-52. PubMed ID: 26876212
[TBL] [Abstract][Full Text] [Related]
18. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer.
Jiang W; He T; Liu S; Zheng Y; Xiang L; Pei X; Wang Z; Yang H
J Hematol Oncol; 2018 Dec; 11(1):139. PubMed ID: 30547809
[TBL] [Abstract][Full Text] [Related]
19. TRIM32 Promotes the Growth of Gastric Cancer Cells through Enhancing AKT Activity and Glucose Transportation.
Wang J; Fang Y; Liu T
Biomed Res Int; 2020; 2020():4027627. PubMed ID: 32051827
[TBL] [Abstract][Full Text] [Related]
20. UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expres7sion of PDK1 through PI3K/AKT signaling.
Lin JX; Xie XS; Weng XF; Qiu SL; Yoon C; Lian NZ; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Yang YH; Huang CM; Zheng CH; Li P
J Exp Clin Cancer Res; 2019 Sep; 38(1):410. PubMed ID: 31533855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
